<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876951</url>
  </required_header>
  <id_info>
    <org_study_id>NeoVAB</org_study_id>
    <nct_id>NCT03876951</nct_id>
  </id_info>
  <brief_title>Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)</brief_title>
  <acronym>NeoVAB</acronym>
  <official_title>Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in&#xD;
      females in the world. Neoadjuvant chemotherapy (NAC) is increasingly used in patients with&#xD;
      operable breast cancer to enhance the likelihood of breast conservation. New generation of&#xD;
      treatments or combinations lead to a high rate of pathological complete responses (pCR) in&#xD;
      patients with human epidermal growth factor receptor 2 positive (HER2) and triple negative&#xD;
      tumours. Safe omission of surgery in patients who receive NAC and achieve radiologic complete&#xD;
      response depends on the ability to accurately estimate pCR preoperatively.&#xD;
&#xD;
      If pathological complete response after NAC could be accurately assessed by VAB, surgery&#xD;
      could be avoided. In the context of new treatments or combinations with an increased pCR&#xD;
      rate, this new strategy could induce major changes in clinical practice, leading to breast&#xD;
      surgery de-escalation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 66 patients will be submitted to percutaneous vacuum-assisted biopsy (VAB),&#xD;
      followed by breast surgery. The primary endpoint of the study is the false negative rate of&#xD;
      VAB procedure. This rate will be calculated by comparing the detection of invasive or in situ&#xD;
      carcinoma on surgical specimen versus VAB samples. The secondary endpoints of the study are&#xD;
      feasibility, VAB procedure technical complications and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 7, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>False negative rate of vacuum-assisted biopsy</measure>
    <time_frame>During the surgery</time_frame>
    <description>Absence of invasive and in-situ carcinoma on vacuum-assisted biopsy but presence of invasive or in-situ carcinoma on the surgical specimen.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Vacuum-assisted Biopsy</condition>
  <arm_group>
    <arm_group_label>vacuum-assisted biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vacuum-assisted biopsy</intervention_name>
    <description>Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery.</description>
    <arm_group_label>vacuum-assisted biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient aged 18 years or older.&#xD;
&#xD;
          2. Written informed consent provided.&#xD;
&#xD;
          3. Triple negative or HER2-positive / ER-negative or HER2-positive / ER-positive breast&#xD;
             tumours.&#xD;
&#xD;
          4. Patients eligible for breast conservation after NAC.&#xD;
&#xD;
          5. Patients with T2-T3 N0 invasive breast cancer initially treated by NAC to allow breast&#xD;
             conservation, who have received a minimum of 6 cycles of adequate NAC +/- anti-HER2.&#xD;
&#xD;
          6. Clinical complete response after NAC.&#xD;
&#xD;
          7. Radiological (mammography, breast US, breast MRI) complete response after NAC.&#xD;
&#xD;
          8. Patients predicted to be node-negative at treatment initiation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient younger than 18 years old.&#xD;
&#xD;
          2. Pregnant or breastfeeding women.&#xD;
&#xD;
          3. Proven metastatic axillary or internal mammary chain lymph node involvement before NAC&#xD;
             proven by biopsy or cytology.&#xD;
&#xD;
          4. Bilateral breast cancer.&#xD;
&#xD;
          5. Contraindication to MRI.&#xD;
&#xD;
          6. Contraindication to breast conservation&#xD;
&#xD;
          7. Patients with a BRCA mutation or other autosomal dominant high-penetrance genetic&#xD;
             predisposition to breast cancer.&#xD;
&#xD;
          8. Patients with limitation of freedom or under guardianship&#xD;
&#xD;
          9. Inability for psychological reasons&#xD;
&#xD;
         10. Hypersensitivity to local anaesthesia&#xD;
&#xD;
         11. Initial imaging showing ACR6 micro calcifications and/or ACR6 non-mass enhancement&#xD;
             associated to the index lesion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles COUTANT</last_name>
    <phone>33.3.80.73.75.00</phone>
    <email>CCoutant@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>03 45 34 81 16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Georges Fran√ßois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie REDERSTORFF</last_name>
      <phone>03 45 34 81 16</phone>
      <email>erederstorff@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Charles COUTANT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>vacuum-assisted biopsy</keyword>
  <keyword>pathological complete response</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

